Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870297 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3025876 in Participants With Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01870297 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT01870297, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG LY3025876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870297
The ClinicalTrials.gov registry entry for NCT01870297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01870297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870297 about?
NCT01870297 is a clinical study titled "A Study of LY3025876 in Participants With Diabetes". The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01870297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01870297?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), LY3025876 (DRUG).
Who is sponsoring clinical trial NCT01870297?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.